Plethico Pharmaceuticals

The decision comes at a time when authorities are clamping down on shell companies - listed as well as unlisted - for being allegedly used as conduits for illicit fund flows.

Stocks in news: Max India, Adani Ent, Biocon, Neyveli, MRPL

Dish TV | Max India | Indian Hotels | Adani Enterprises | MRPL | Tata Steel | Jaiprakash Associates | Jaypee Infratech | Biocon | Neyveli Lignite | CMC | Jet Airways and Inox Wind are stocks, which are in the news today.

Aurobindo, Plethico rally post settlement over Natrol USA

Shares of Aurobindo Pharma gained more than 2 percent intraday and Plethico Pharmaceuticals rallied 20 percent on Thursday on settlement agreement related to acquisition of Natrol, USA.

Plethico Pharma consolidated Dec '14 sales at Rs 111.45 crore

Plethico Pharmaceuticals has reported a consolidated total income from operations of Rs 111.45 crore and a net loss of Rs 4.07 crore for the quarter ended Dec '14

Plethico Pharma consolidated Dec '13 sales at Rs 364.38 crore

Plethico Pharmaceuticals has reported a sales turnover of Rs 364.38 crore and a net profit of Rs 44.07 crore for the quarter ended Dec '13

BSE, NSE to shift scrips to restricted group from Nov 22

The move is part of a surveillance review to safeguard interest of investors in the capital market.

Plethico Pharma consolidated Sep '13 sales at Rs 470.69 crore

Plethico Pharmaceuticals has reported a sales turnover of Rs 470.69 crore and a net profit of Rs 20.97 crore for the quarter ended Sep '13

Plethico Pharma consolidated Jun '13 sales at Rs 518.21 crore

Plethico Pharmaceuticals has reported a sales turnover of Rs 518.21 crore and a net profit of Rs 44.40 crore for the quarter ended Jun '13

Plethico Pharma consolidated Mar '13 sales at Rs 490.50 crore

Plethico Pharmaceuticals has reported a sales turnover of Rs 490.50 crore and a net profit of Rs 13.23 crore for the quarter ended Mar '13

Plethico Pharmaceuticals touches 5% upper circuit

Plethico Pharmaceuticals is locked at 5 percent upper circuit on Tuesday after seeing a fall of 8.5 percent in previous two straight sessions.

Only buyers in Plethico Pharma, stock up 5%

In the Plethico Pharmaceuticals there were pending buy orders of 17,878 shares, with no sellers available. At 14:30 hrs the share was quoting at Rs 221.90, up Rs 10.55, or 4.99 percent.

Only buyers in Plethico Pharma, shares up 5% for 4th day

Plethico Pharmaceuticals is locked at 5 percent upper circuit for the fourth consecutive session on Monday.

Buy Plethico Pharma, JP Power, Shriram Transport: Tulsian

In CNBC-TV18's popular show Bull's Eye, SP Tulsian, sptulsian.com shares trading strategy of the day.

Buy Plethico Pharma, Anant Raj; Sell Rel Comm: Tulsian

In CNBC-TV18's popular show Bull's Eye, SP Tulsian of sptulsian.com shares trading strategy of the day.

Buy Plethico Pharma, Guj NRE, Suzlon Energy: SP Tulsian

In CNBC-TV18's popular show Bull's Eye, SP Tulsian of sptulsian.com shares trading strategy of the day.

Plethico Pharma plunges for 5th consecutive session

Plethico Pharmaceuticals has been drifting lower and lower for the fifth consecutive session on Thursday. The stock has touched a new 52-week low and three-year low of Rs 193.05.

Plethico Pharma hits 3-year low, down 37% in 4 days

Plethico Pharmaceuticals has touched a three-year low of Rs 214.45 on Wednesday due to consistent selling pressure. The stock plunged 37.5% in four consecutive sessions.

Buy Dishman Pharma, Plethico Pharma:Rajesh Agarwal

In CNBC-TV18's popular show Bull's Eye, Rajesh Agarwal, Eastern Financiers shares trading strategy of the day.

Govt clears 25 FDI proposals worth Rs 2,973 crore

The government today said it has cleared 25 foreign direct investment (FDI) proposals, including that of AIF III of Mauritius and Mumbai based Microqual Techno, worth Rs 2,973.40 crore.

CRISIL assigns valuation grade of 5/5 to Plethico Pharma

CRISIL Research has come out with its report on Plethico Pharmaceuticals. The research firm has assigned a valuation grade of 5/5 to the company and assigned fundamental grade of 3/5 in its August 17, 2011 report.

CRISIL assigns valuation grade of 5/5 to Plethico Pharma

CRISIL Research has come out with its report on Plethico Pharmaceuticals. The research firm has initiated coverage on the company with a Valuation Grade of ‘5/5’ and has maintained the fair value of Rs 530 per share.

CRISIL assigns valuation grade of 5/5 to Plethico Pharma

CRISIL Research has come out with its report on Plethico Pharmaceuticals. The research firm has initiated coverage on Plethico Pharmaceuticals with a Valuation Grade of ‘5/5’ and has maintained the fair value of Rs 530 per share.

CRISIL assigns valuation grade of 5/5 to Plethico Pharma

CRISIL Research has come out with its report on Plethico Pharmaceuticals. The research firm has initiated coverage on Plethico Pharmaceuticals with a Valuation Grade of ‘5/5’ and maintain the fair value of Rs 530 per share.

Expect around 18-20% growth going forward: Plethico Pharma

Sanjay Pai, CFO, Plethico Pharmaceuticals says, the company grew about 22% year-on-year. He further says, the company has been growing at a steady rate of 18-20%. He expects similar kind of growth going forward.